Citi Adjusts Revenue Forecasts for Shanghai Pharmaceuticals (02607.HK)
Citi has lowered the target price for Shanghai Pharmaceuticals (02607.HK) to HKD 13.5, adjusting revenue forecasts for 2026 following shifts in the Chinese pharmaceutical landscape. This adjustment reflects broader regulatory ... Read More